# Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML

> **NCT07511062** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Northside Hospital, Inc.** · enrollment: 32 (estimated)

## Conditions studied

- Acute Myeloid Leukemia
- TP53 Gene Mutation

## Interventions

- **DRUG:** Decitabine
- **DRUG:** Venetoclax
- **DRUG:** Axatilimab

## Key facts

- **NCT ID:** NCT07511062
- **Lead sponsor:** Northside Hospital, Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-01
- **Primary completion:** 2029-08-01
- **Final completion:** 2030-08-01
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2026-04-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07511062

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07511062, "Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07511062. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*